Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,349 result(s) found. Displaying page 1,312 of 2,218.
    «« First « Previous 1308  1309  1310  1311  1312  1313  1314  1315  1316  Next» Last»»
    EudraCT Number: 2004-000023-15 Sponsor Protocol Number: H7T-MC-TAAL Start Date*: 2005-02-10
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects who are to Undergo Percutaneous Coronary Intervention
    Medical condition: Reduction of atherothrombotic events in patients with acute coronary syndromes (ACS) that is patients with ST-segment elevation MI [STEMI], non-ST-segment elevation MI [NSTEMI], or unstable angina...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10011085 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) AT (Completed) FI (Completed) HU (Completed) CZ (Completed) SK (Completed) DE (Completed) IT (Completed) LT (Completed) EE (Completed) LV (Completed) IS (Completed) ES (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-004351-35 Sponsor Protocol Number: BAY 59-7939/11354 Start Date*: 2006-01-11
    Sponsor Name:Bayer HealthCare AG
    Full Title: RECORD 1 Study: REgulation of Coagulation in ORthopedic Surgery to prevent DVT and PE, controlled, double-blind, randomized study of BAY 59-7939 in the extended prevention of VTE in patients underg...
    Medical condition: Prevention of venous thromboembolism
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012108 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) AT (Completed) DK (Completed) BE (Completed) LT (Completed) HU (Completed) SK (Completed) ES (Completed) IT (Completed) FI (Completed) CZ (Completed) DE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2005-002313-21 Sponsor Protocol Number: TAK-475/EC302 Start Date*: 2005-09-29
    Sponsor Name:Takeda Europe Research & Development Limited
    Full Title: A placebo-controlled, double-blind, randomized study to evaluate the efficacy and safety of TAK-475 50mg and 100mg versus placebo, when co-administered with simvastatin 20mg or 40mg in subjects wit...
    Medical condition: Treatment of patients with primary dyslipidaemia currently taking simvastatin 20mg or 40mg
    Disease: Version SOC Term Classification Code Term Level
    8 10058108 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FI (Completed) EE (Completed) CZ (Completed) DE (Completed) LV (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-002315-25 Sponsor Protocol Number: TAK-475/EC303 Start Date*: 2005-12-15
    Sponsor Name:Takeda Europe R&D Centre Ltd
    Full Title: A double-blind, double dummy, randomized, parallel group, multi-centre Phase III study to evaluate the efficacy and safety of TAK-475 100 mg and TAK-475 100 mg administered in combination with ezet...
    Medical condition: Treatment of patients with primary dyslipidaemia
    Disease: Version SOC Term Classification Code Term Level
    8 10058108 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) EE (Completed) FI (Completed) LV (Completed) LT (Completed) HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001477-94 Sponsor Protocol Number: 3098B1-203 Start Date*: 2006-05-08
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development
    Full Title: A 6-MONTH, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, MULTICENTER, SAFETY, TOLERABILITY, AND EFFICACY STUDY OF 3 DOSES OF LECOZOTAN (SRA-333) SR IN OUTPATIENTS WITH MILD TO MODERATE ALZHEIMER’S...
    Medical condition: Alzheimer's Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FI (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-000031-26 Sponsor Protocol Number: R256918DIA2001 Start Date*: 2007-12-18
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A 12-Week, Double-Blind, Randomized, Placebo-Controlled Study in Type 2 Diabetes Mellitus Subjects to Evaluate the Efficacy, Safety and Tolerability of MTP Inhibitor JNJ-16269110
    Medical condition: Diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018424 Glucose metabolism disorders (incl diabetes mellitus) HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) FI (Completed) NL (Completed) SE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-000403-15 Sponsor Protocol Number: 01-06-TL-375-081 Start Date*: 2007-07-25
    Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Polysomnography plus Outpatient Study to Determine the Safety and Efficacy of 4 mg Ramelteon in Adults with Chronic Insomnia
    Medical condition: insomnia characterised by difficulty with sleep onset
    Disease: Version SOC Term Classification Code Term Level
    9.1 10053851 Chronic insomnia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) FI (Completed) DE (Completed) FR (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-003894-26 Sponsor Protocol Number: 1160.26 Start Date*: 2005-12-23
    Sponsor Name:Boehringer Ingelheim AB
    Full Title: Randomized Evaluation of Long term anticoagulant therapy (RE-LY) comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke...
    Medical condition: Prevention of Stroke and Systemic Embolism in patients with Atrial Fibrillation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) FI (Completed) CZ (Completed) AT (Completed) HU (Completed) DE (Completed) SK (Completed) IT (Completed) ES (Completed) GB (Completed) PT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2007-002492-14 Sponsor Protocol Number: EFC10139 Start Date*: 2008-03-28
    Sponsor Name:sanofi-aventis recherche & developpement
    Full Title: A randomized, double-blind, parallel-group, multicenter, multinational study to assess the long-term effect, over 1 year, of rimonabant 10 mg in comparison with rimonabant 20 mg after an initial tr...
    Medical condition: Patients with BMI > or = 30 kg/m2 or BMI > 27 kg/m2 with associated risk factors such as Type 2 Diabetes mellitus or Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    10.1 10045260 LLT
    10.1 10058108 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) NL (Prematurely Ended) FI (Completed)
    Trial results: View results
    EudraCT Number: 2007-002410-19 Sponsor Protocol Number: 1235.7 Start Date*: 2007-09-26
    Sponsor Name:Boehringer Ingelheim bv
    Full Title: An open label follow-up trial of the efficacy and safety of chronic administration of the combination of telmisartan 40mg + amlodipine 5mg or the combination of telmisartan 80mg + amlodipine 5mg ta...
    Medical condition: essential hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015488 Essential hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FI (Completed) BE (Completed) SE (Completed) DK (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-005134-36 Sponsor Protocol Number: 1184.14 Start Date*: 2008-01-28
    Sponsor Name:Boehringer Ingelheim bv
    Full Title: A 24-week (+ 24 week extension), randomized, placebo-controlled (only 1st 12-week period), double–blind, parallel-group, efficacy and safety comparison of Tiotropium/Salmeterol (7.5 µg/25 µg) Inhal...
    Medical condition: Moderate to severe COPD
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    9.1 10010953 COPD exacerbation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) ES (Completed) FI (Completed) PT (Prematurely Ended) DE (Prematurely Ended) BE (Completed) DK (Completed) FR (Completed) SE (Prematurely Ended) IT (Prematurely Ended) LV (Prematurely Ended) GR (Completed) LT (Prematurely Ended) EE (Prematurely Ended) SK (Completed) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005107-17 Sponsor Protocol Number: 1184.15 Start Date*: 2008-01-28
    Sponsor Name:Boehringer Ingelheim bv
    Full Title: A 24-week (+ 24 week extension), randomized, placebo-controlled (only 1st 12-week period), double–blind, parallel-group, efficacy and safety comparison of Tiotropium/Salmeterol (7.5 µg/25 µg) Inhal...
    Medical condition: Moderate to severe COPD
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    9.1 10010953 COPD exacerbation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) ES (Completed) FI (Completed) DE (Prematurely Ended) PT (Prematurely Ended) BE (Completed) FR (Completed) SE (Prematurely Ended) DK (Prematurely Ended) LV (Prematurely Ended) HU (Prematurely Ended) LT (Prematurely Ended) EE (Prematurely Ended) GR (Prematurely Ended) IT (Prematurely Ended) AT (Prematurely Ended) SK (Completed)
    Trial results: View results
    EudraCT Number: 2008-001724-32 Sponsor Protocol Number: D0570C00007 Start Date*: 2008-06-20
    Sponsor Name:AstraZeneca AB
    Full Title: A phase II, double-blind, placebo-controlled, randomised, 6-way cross-over, single-dose study to investigate the local and systemic effects of 3 doses of inhaled AZD3199 (a β2-agonist) compared to ...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003553 Asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2007-002536-29 Sponsor Protocol Number: 27905 Start Date*: 2008-03-03
    Sponsor Name:Merck Serono International
    Full Title: A randomised, double-blind, placebo controlled, multi-centre phase II study of atacicept in anti- TNF alfa-naïve patients with moderate to severely active rheumatoid arthritis and an inadequate res...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) AT (Completed) FI (Completed) SE (Completed) CZ (Completed) BE (Completed) PT (Completed) DE (Completed) IT (Completed) PL (Completed) GR (Completed) ES (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004949-34 Sponsor Protocol Number: 248.595 Start Date*: 2006-04-18
    Sponsor Name:Boehringer Ingelheim Austria GmbH
    Full Title: A randomized, double-blind, placebo-controlled, parallel-group clinical trial to examine the efficacy and safety of early pramipexole treatment versus delayed pramipexole treatment in patients with...
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    6.1 10061536 pref
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) GB (Completed) SE (Completed) DE (Completed) ES (Completed) FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-002536-94 Sponsor Protocol Number: 1160.47 Start Date*: 2006-03-20
    Sponsor Name:Boehringer Ingelheim Finland Ky
    Full Title: A phase III, randomised, multicenter, double-blind, parallel-group, active controlled study to evaluate the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2...
    Medical condition: Confirmed Venous Thromboembolism (VTE) i.e. uni or bilateral deep vein thrombosis (DVT) of the leg involving proximal veins and/or pulmonay embolism (PE) - treated with anticoagulant for 3 to 6 mo...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) AT (Completed) SE (Completed) CZ (Completed) BE (Completed) SK (Completed) GB (Completed) ES (Completed) DE (Completed) HU (Completed) PT (Completed) GR (Completed) DK (Completed) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2006-004481-13 Sponsor Protocol Number: NN8022-1807 Start Date*: 2006-10-18
    Sponsor Name:Novo Nordisk A/S [...]
    1. Novo Nordisk A/S
    2. Novo Nordisk A/S
    Full Title: Effect of liraglutide on body weight in obese subjects without diabetes A 20-week randomised, double-blind, placebo-controlled, six armed parallel group, multi-centre, multinational trial with an o...
    Medical condition: obesity
    Disease: Version SOC Term Classification Code Term Level
    9.0 10012601 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) FI (Completed) DK (Completed) NL (Completed) BE (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-002901-38 Sponsor Protocol Number: 12541A Start Date*: 2009-04-20
    Sponsor Name:H. Lundbeck A/S
    Full Title: Randomised, double-blind, parallel-group, placebo-controlled, duloxetine-referenced, fixed dose study comparing the efficacy and safety of Lu AA21004 in acute treatment of major depressive disorder...
    Medical condition: Major depressive disorder in elderly patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025453 Major depressive disorder NOS LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) FR (Completed) FI (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2004-003733-14 Sponsor Protocol Number: WA17823 Start Date*: 2005-03-23
    Sponsor Name:F. Hoffmann La-Roche Ltd.
    Full Title: A randomized, double-blind, parallel group study of the safety and prevention of structural joint damage during treatment with MRA versus placebo, in combination with methotrexate, in patients with...
    Medical condition: Rheumatoid Arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DK (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-000320-14 Sponsor Protocol Number: D6997L00002 (9238SW0001) Start Date*: 2006-03-29
    Sponsor Name:AstraZeneca oy
    Full Title: Anastrozole monotherapy versus maximal oestrogen blockage with anastrozole and fulvestrant comination therapy: An open, randomised, comparative, phase III multicentre study in postmenopausal women ...
    Medical condition: Hormone receptor positive breast cancer in first relapse after primary treatment of localised tumour, in postmenopausal women.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FI (Completed) PT (Completed) IS (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 1308  1309  1310  1311  1312  1313  1314  1315  1316  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jul 17 10:00:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA